文献速递炎症性肠病

Upadacitinib治疗克罗恩病的随机试验疗效与安全性

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
PubMed 文献 · Gastroenterology · 2020-02-08

这项双盲2期试验纳入220例中重度克罗恩病且对免疫抑制剂或TNF拮抗剂应答不足或不耐受的成人患者,评估口服选择性JAK1抑制剂Upadacitinib的诱导与维持治疗。结果显示部分剂量组内镜缓解率显著高于安慰剂,且内镜缓解随剂量增加而提高,但感染及血脂升高风险需关注。

要点

  • Upadacitinib部分剂量组内镜缓解率显著优于安慰剂(0%)。
  • 内镜缓解随诱导期剂量增加而提高,临床缓解未见此趋势。
  • 诱导期Upadacitinib组感染及严重感染发生率高于安慰剂。

核心结论

  • Upadacitinib在中重度克罗恩病2期试验中较安慰剂显著诱导内镜缓解,其获益/风险特征支持进一步开发。

研究设计与样本

  • 双盲2期试验,纳入220例中重度克罗恩病且对免疫抑制剂或TNF拮抗剂应答不足或不耐受的成人患者。
  • 按1:1:1:1:1:1随机分为安慰剂组、Upadacitinib 3/6/12/24 mg每日两次组及24 mg每日一次组,第12或16周行回结肠镜评估。
  • 完成第16周者重新随机进入36周维持治疗期。

主要发现

  • 临床缓解率:3 mg组13%、6 mg组27%(P < .1 vs 安慰剂)、12 mg组11%、24 mg每日两次组22%、24 mg每日一次组14%,安慰剂组11%。
  • 内镜缓解率分别为10%(P < .1)、8%、8%(P < .1)、22%(P < .01)、14%(P < .05),安慰剂组为0%。
  • 内镜缓解而非临床缓解在诱导期随剂量增加而提高,多数终点疗效维持至第52周。
  • 诱导期Upadacitinib组感染和严重感染发生率高于安慰剂。
  • 每日两次12 mg和24 mg组总胆固醇、高密度脂蛋白和低密度脂蛋白胆固醇水平较安慰剂组显著升高。

关键数值与推荐

  • 主要终点为第16周临床缓解及第12或16周内镜缓解,采用多重比较程序与建模及Cochran-Mantel-Haenszel检验,双侧检验水准10%。

临床怎么用

  • Upadacitinib可能作为中重度克罗恩病经免疫抑制剂或TNF拮抗剂治疗失败后的候选药物,用药时需监测感染及血脂变化。

局限性

  • 为2期试验,样本量220例,疗效与安全性需更大规模3期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We evaluated the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patients with Crohn's disease (CD). METHODS: We performed a double-blind, phase 2 trial in adults with moderate to severe CD and inadequate response or intolerance to immunosuppressants or tumor necrosis factor antagonists. Patients were randomly assigned (1:1:1:1:1:1) to groups given placebo; or 3 mg, 6 mg, 12 mg, or 24 mg upadacitinib twice daily; or 24 mg upadacitinib once daily and were evaluated by ileocolonoscopy at weeks 12 or 16 of the induction period. Patients who completed week 16 were re-randomized to a 36-week period of maintenance therapy with upadacitinib. The primary endpoints were clinical remission at week 16 and endoscopic remission at week 12 or 16 using the multiple comparison procedure and modeling and the Cochran-Mantel-Haenszel test, with a 2-sided level of 10%. RESULTS: Among the 220 patients in the study, clinical remission was achieved by 13% of patients receiving 3 mg upadacitinib, 27% of patients receiving 6 mg upadacitinib (P < .1 vs placebo), 11% of patients receiving 12 mg upadacitinib, and 22% of patients receiving 24 mg upadacitinib twice daily, and by 14% of patients receiving 24 mg upadacitinib once daily, vs 11% of patients receiving placebo. Endoscopic remission was achieved by 10% (P < .1 vs placebo), 8%, 8% (P < .1 vs placebo), 22% (P < .01 vs placebo), and 14% (P < .05 vs placebo) of patients receiving upadacitinib, respectively, vs none of the patients receiving placebo. Endoscopic but not clinical remission increased with dose during the induction period. Efficacy was maintained for most endpoints through week 52. During the induction period, patients in the upadacitinib groups had higher incidences of infections and serious infections vs placebo. Patients in the twice-daily 12 mg and 24 mg upadacitinib groups had significant increases in total, high-density lipoprotein, and low-density lipoprotein cholesterol levels compared with patients in the placebo group. CONCLUSIONS: In a phase 2 trial of patients with CD, upadacitinib induced endoscopic remission in a significant proportion of patients compared with placebo. Upadacitinib's benefit/risk profile supports further development for treatment of CD. (Clinicaltrials.gov, Number: NCT02365649).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020. PMID: 32044319. doi:10.1053/j.gastro.2020.01.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。